ASX - Delayed Quote AUD

Cooper Metals Limited (CPM.AX)

0.0370

0.0000

(0.00%)

At close: 3:40:25 PM GMT+10

Trump-Musk fight reveals fragility of relationship between Silicon Valley and White House

The falling out between President Trump and Elon Musk is just the latest reminder that the relationship between the new White House and the titans of technology has turned out to be complicated.

Yahoo Finance 16 hours ago

MSFT

AMZN

NVDA
Palantir Price Target Raised to $155 on 'Explosive' AI Potential

Loop Capital Lifts Palantir Target to $155 After CFO Meeting

GuruFocus.com 3 minutes ago

PLTR
Roku stock surges on Amazon Ads partnership

Investing.com -- Roku shares surged 9.8% premarket on Monday after the company announced an exclusive partnership with Amazon (NASDAQ:AMZN) Ads, creating what the firms describe as the “largest authenticated Connected TV (CTV) footprint in the U.S.”

Investing.com 13 minutes ago

ROKU

AMZN

DIS
Critical Metals Corp Secures US$120,000,000 LOI for a 15-Year Term Loan From the US Federal Government Bank (EXIM Bank) for the Development of its Tanbreez Rare Earth Project in Greenland

Non-dilutive funding package expected to be sufficient to enable the Tanbreez Project to complete pre-production activities and commence miningNEW YORK, June 16, 2025 (GLOBE NEWSWIRE) -- Critical Metals Corp. (Nasdaq: CRML) (“Critical Metals Corp” or the “Company”), a leading critical minerals mining company, today announced that it has received a Letter of Interest from the Export-Import Bank of the United States (EXIM), for a total non-dilutive funding package of $120 million. This funding pac

GlobeNewswire 31 minutes ago

CRML

CRMLW
Sarepta and Roche halt DMD gene therapy’s use after second death

Shares in both companies were down following news of the second death, casting fresh safety concerns over Elevidys.

Pharmaceutical Technology 35 minutes ago

ROG.SW

SRPT
Palantir 'Golden Dome' Upside Eyed Amid High Valuation. Is Palantir Stock A Buy Or Sell?

Palantir stock bulls tout the software maker's artificial intelligence strategy and potential to win more U.S. government contracts.

Investor's Business Daily 40 minutes ago

PLTR
Sage Therapeutics Stock Soars 35% After Sale to Supernus Pharmaceuticals. What We Know.

Supernus Pharmaceuticals signed a definitive agreement to acquire fellow biopharmaceutical company Sage Therapeutics for $8.50 a share in a deal worth an initial $561 million. The terms also includes one non-tradable contingent value right ( CVR ) payable upon achieving certain sales goals, which could bring Sage shareholders an additional $3.50 a share and $234 million by the end of 2030. The main draw of the deal for Supernus is Sage’s drug Zurzuvae, the first and only oral medication approved by the Food and Drug Administration for treatment of postpartum depression.

Barrons.com 49 minutes ago

SAGE

SUPN
Supernus Pharmaceuticals to Acquire Sage Therapeutics, Strengthening its Neuropsychiatry Product Portfolio

Proposed acquisition expected to accelerate mid- to long-term revenue and cash flow growth and further diversify revenue base.Strengthens Supernus’ leading presence in neuropsychiatric conditions with an innovative commercial product, ZURZUVAE® (zuranolone), and a novel CNS discovery platform.Expected to be significantly accretive in 2026 with potential cost synergies of up to $200 million on an annual basis.Upfront cash payment of $8.50 per share, plus one non-tradable contingent value right (C

GlobeNewswire 1 hour ago

SAGE

SUPN
Market Chatter: EchoStar's Spectrum Crisis Draws White House Intervention; Shares Rise Pre-Bell

EchoStar (SATS) shares rose more than 48% in Monday's premarket activity as President Donald Trump s

PREMIUM
MT Newswires 1 hour ago

SATS
Billionaire Terry Smith, "the English Warren Buffett," Is Selling Meta Platforms and Microsoft and Buying This Stock That's Trouncing the Market in 2025

It's not too late to buy into the latest addition to Smith's hedge fund portfolio.

Motley Fool 1 hour ago

MSFT

META

INTU
These Stocks Are Moving the Most Today: Sarepta, Tesla, U.S. Steel, Victoria’s Secret, Lennar, and More

Sarepta Therapeutics falls sharply after suspending shipments of Elevidys for infusions in non-ambulatory patients because of the death of a second patient from acute liver failure.

Barrons.com 2 hours ago

LEN-B

X

TSLA
Sarepta Stock Plunges After Death of Second Patient Receiving Its Gene Therapy

A second patient receiving its experimental gene therapy Elevidys has died from liver failure, raising serious questions on the drug’s outlook.

Barrons.com 2 hours ago

SRPT

ROG.SW
Meta Investors Cheer as Zuckerberg Doubles Down on AI Commitment

(Bloomberg) -- Meta Platforms Inc. keeps writing bigger checks in pursuit of its artificial intelligence strategy, and traders keep cheering it on, encouraged that the expensive bets will keep paying off.Most Read from BloombergShuttered NY College Has Alumni Fighting Over Its FutureDo World’s Fairs Still Matter?As Part of a $45 Billion Push, ICE Prepares for a Vast Expansion of Detention SpaceNYC Renters Brace for Price Hikes After Broker-Fee BanAs American Architects Gather in Boston, Retrofit

Bloomberg 2 hours ago

NVDA

GOOG

META
Trending tickers: US Steel, Kering, Tata Motors, BP and Entain

The latest investor updates on stocks that are trending on Monday.

Yahoo Finance UK 2 hours ago

RYDAF

SHEL

TATAMOTORS.NS
Big Tech’s Furious Rally Forces Options Pros to Line Up Hedges

(Bloomberg) -- Big Tech has led the furious rebound in US stocks from the tailspin that followed President Donald Trump’s sweeping April 2 tariff edict. Now options traders are signaling that they see the pricey cohort as especially vulnerable to another round of trade war-driven volatility.Most Read from BloombergShuttered NY College Has Alumni Fighting Over Its FutureDo World’s Fairs Still Matter?As Part of a $45 Billion Push, ICE Prepares for a Vast Expansion of Detention SpaceNYC Renters Bra

Bloomberg 3 hours ago

GOOG

AMZN

META
Will IonQ Stock Trounce Palantir in the Second Half of 2025?

IonQ and Palantir are surfing two big tech waves -- quantum computing and AI. While Palantir is larger and already profitable, IonQ's revenue could grow faster this year. Few stocks have been as hot as Palantir Technologies (NASDAQ: PLTR) in 2025.

Motley Fool 3 hours ago

PLTR

IONQ-WS
Bitcoin Buyer Metaplanet Is Now Bigger Than Chipmaker Kioxia

(Bloomberg) -- Japan’s hotelier-turned-Bitcoin-buyer Metaplanet Inc. overtook memory chipmaker Kioxia Holdings Corp. in terms of market capitalization as the stock soared nearly 400% in less than two months, riding the global crypto rally.Most Read from BloombergShuttered NY College Has Alumni Fighting Over Its FutureDo World’s Fairs Still Matter?As Part of a $45 Billion Push, ICE Prepares for a Vast Expansion of Detention SpaceNYC Renters Brace for Price Hikes After Broker-Fee BanAs American Ar

Bloomberg 4 hours ago

MTPLF

285A.T
Where Will Palantir Technologies Stock Be in 1 Year?

An impressive surge in the past few months has boosted Palantir stock to extremely expensive valuation levels. Palantir's potential to gain a bigger share of the AI software market could propel the stock higher despite the negative sentiment. Palantir Technologies' (NASDAQ: PLTR) stock has been in crushing form on the market over the past year, rising by a stunning 482% as of this writing.

Motley Fool 4 hours ago

PLTR
My Top 5 AI Stocks to Buy Before the Second Half

AI stocks drove market gains over the past two years, but earlier this year they led declines. Investors, worried about the potential impact of import tariffs on the economy, avoided growth stocks. The first half of the year was a turbulent one for stocks in general amid concern President Trump's planned import tariffs would hurt the economy.

Motley Fool 4 hours ago

NVDA

AAPL

PLTR
Billionaire Stanley Druckenmiller Dumped His Entire Stake in Palantir and Has Piled Into This Suddenly Unstoppable Drug Stock for 3 Straight Quarters

Duquesne Family Office's billionaire chief sold every share of Wall Street's hottest artificial intelligence (AI) stock in favor of a drugmaker whose shares have surged 142% in two years.

Motley Fool 5 hours ago

PLTR

TEVA

Performance Overview

Return	CPM.AX	S&P/ASX 200 [XJO] (^AXJO)
YTD	-16.85%	+4.77%
1-Year	-50.67%	+10.67%
3-Year	-90.39%	+29.70%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Cooper Metals Limited (CPM.AX)

Related News

Trump-Musk fight reveals fragility of relationship between Silicon Valley and White House

Palantir Price Target Raised to $155 on 'Explosive' AI Potential

Roku stock surges on Amazon Ads partnership

Critical Metals Corp Secures US$120,000,000 LOI for a 15-Year Term Loan From the US Federal Government Bank (EXIM Bank) for the Development of its Tanbreez Rare Earth Project in Greenland

Sarepta and Roche halt DMD gene therapy’s use after second death

Palantir 'Golden Dome' Upside Eyed Amid High Valuation. Is Palantir Stock A Buy Or Sell?

Sage Therapeutics Stock Soars 35% After Sale to Supernus Pharmaceuticals. What We Know.

Supernus Pharmaceuticals to Acquire Sage Therapeutics, Strengthening its Neuropsychiatry Product Portfolio

Market Chatter: EchoStar's Spectrum Crisis Draws White House Intervention; Shares Rise Pre-Bell

Billionaire Terry Smith, "the English Warren Buffett," Is Selling Meta Platforms and Microsoft and Buying This Stock That's Trouncing the Market in 2025

These Stocks Are Moving the Most Today: Sarepta, Tesla, U.S. Steel, Victoria’s Secret, Lennar, and More

Sarepta Stock Plunges After Death of Second Patient Receiving Its Gene Therapy

Meta Investors Cheer as Zuckerberg Doubles Down on AI Commitment

Trending tickers: US Steel, Kering, Tata Motors, BP and Entain

Big Tech’s Furious Rally Forces Options Pros to Line Up Hedges

Will IonQ Stock Trounce Palantir in the Second Half of 2025?

Bitcoin Buyer Metaplanet Is Now Bigger Than Chipmaker Kioxia

Where Will Palantir Technologies Stock Be in 1 Year?

My Top 5 AI Stocks to Buy Before the Second Half

Billionaire Stanley Druckenmiller Dumped His Entire Stake in Palantir and Has Piled Into This Suddenly Unstoppable Drug Stock for 3 Straight Quarters

Performance Overview